|

|

close search icon

Company Profile

Corporate Culture

Management Team

Company History

Message from the CEO

Honors and Awards

Over 19 years of experience in R&D

01 Drug Discovery

Chemistry Research

Fee For Service(FFS)

Full Time Equivalent(FTE)

Medicinal Chemistry

Synthetic Chemistry

Analytical Chemistry

Biology Research

Structural Biology

Computational Biology & Molecular Modeling

Enzymology & Molecular Interactions

Early Pharmacokinetics

02 Pharmaceutical Research

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Preformulation Study

Formulation Technology Research

Preparation Quality Research

Laboratory-scale Preparation Testing

Pilot-scale Preparation Testing

GMP-based Clinical Sample Production & Packaging

Formulation Stability Study

Consistency Evaluation

Analytical Method Development and Quality Control

03 Preclinical Research

Pharmacology & Pharmacodynamics

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

Pharmacokinetics

In Vitro Pharmacokinetic Assays

In Vivo Pharmacokinetic Assays

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

01 One-stop Integrated Services

Pharmaceutical Research Platform

Drug Discovery Plarform

One-stop API Process R&D Department

Translational Medicine Platform

Pharmaceutical Research CDMO Service Platform

Chemical Drug Development

Medicilon's CDMO Service Platform

Preclinical Research Services

02 Key Technical Services for Drug R&D

Process Department Solid Form Screening Platform

SEND Format Conversion Platform

Flow Cytometry Technology Platform

Safety Assessment Lab of Process Chemistry

Drug Forming Research Platform

Metabolite Identification (MetID) Service Platform

Cytokine and Biomarker Detection Platform

03 Innovative Drug Services

Nucleic Acid Drug R&D Platform

Non-clinical Research for Cellular Immunotherapies

mRNA Vaccine Bioanalysis Platform

PROTAC Drug Discovery Research Platform

ADC R&D Service Platform

04 Drug Efficacy Evaluation for Common Diseases

Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases

IO Pharmacodynamic Model Evaluation Platform

05 Advanced Preparation R&D

Skin Topical Preparation R&D

Ophthalmic drug R&D platform

Inhalation drug R&D platform

06 Drug Analysis

07 Public Services

Intellectual Property Protection

U.S.

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Medicilon Events

Featured Stories

2023-03-20Market Events

Join Medicilon at SAPA-GP 2023 Annual Conference

Date: 3.31-4.1 2023

Location: King of Prussia, Pennsylvania

2023-03-14Market Events

Join Medicilon at BioTrinity 2023: Catalysing Growth in the Life Sciences Industry

Date: April 25-26, 2023

Location: Etc. venues 155 Bishopsgate, London

Stock Information

Investment Contact

Medicilon 688202

RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

Talent Development

Employee Activities

Campus Recruitment

Social Recruitment

Campus Recruitment

Campus Recruitment

Social Recruitment

Social Recruitment

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

ABOUT
Company Profile Management Team Honors and Awards Corporate Culture

SERVICES
Drug Discovery Pharmaceutical Research Preclinical Research

PLATFORM
One-stop Integrated Services Key Technical Services for Drug R&D Innovative Drug R&D Services Drug Efficacy Evaluation for Common Diseases Advanced Preparation R&D

CLIENT CENTER
Intellectual Property Protection Downloads Partnerships Newsletters

NEWS
Medicilon Events Featured Stories Market Events Videos A.C.E.

INVESTORS
Stock Information Investment Contact

CAREERS
Talent Development Employee Activities Campus Recruitment Social Recruitment

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 |Website Map

关闭

Contact Us

Business Inquiry

Global：

Email:marketing@medicilon.com

+1(626)986-9880(U.S. - West Coast)

0044 7790 816 954 (Europe)

China：

Email: marketing@medicilon.com.cn

Tel: +86 (21) 5859-1500

Message

Back To Top

Online Message×

Medicilon Events

News and Events

Medicilon Events Featured Stories Market Events Videos A.C.E.

HomenewsMedicilon Events

Medicilon Events

Hot information：

Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model

The 19th Annual San Diego BioPharma Conference

Agenda 9:00 am Welcome and Opening Remarks Tao Wu, PhD, President, SABPA Yi Liu, PhD, Chair, BioPharmaCommittee, SABPA; CEO, Kumqat Biosciences 9:15 am Floyd Romesberg,

The 19th Annual San Diego BioPharma Conference

Medicilon won the "Science and Technology Innovation Service Demonstration Case" Award

Shanghai Medicilon Inc. (Medicilon) "Internet + One-Stop Preclinical R&D Service Platform" was awarded the "Science and Technology Innovation Service Demonstration Case” award.

Medicilon won the "Science and Technology Innovation Service Demonstration Case" Award

Medicilon appoints Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department

Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department. Dr. Hong

Medicilon appoints Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department

Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism

Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism

Kumquat Biosciences and Eli Lilly have reached a partnership to jointly develop tumor immune small molecule drugs

Recently, Loxo Oncology, a research and development group of Eli Lilly, and Kumquat Biosciences (Kumquat) announced that the two parties have reached an exclusive collaboration

Kumquat Biosciences and Eli Lilly have reached a partnership to jointly develop tumor immune small molecule drugs

Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team examined Medicilon

On August 4, 2021, Mr. Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team visited Shanghai Medicilon Inc. (Medicilon) at

Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team examined Medicilon

Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use

Recently, Shanghai Ringene Biopharma (Ringene) announced that the company's self-developed anti-tumor class I new drug SHP2 allosteric inhibitor RG001 tablet has been approved for clinical

Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use

Medicilon assists Leado Pharma to obtain clinical approval for small molecule inhibitor LDS tablets targeting transient receptor potential channels

On July 28, 2021, the Class 1 innovative drug LDS tablets developed by Shanghai Leado Pharma Technology Co., Ltd. (Leado Pharma) received the National Medical

Medicilon assists Leado Pharma to obtain clinical approval for small molecule inhibitor LDS tablets targeting transient receptor potential channels

[Medicilon Assist] QHRD110 Capsules, a Class 1 Anti-cancer Drug Targeted by Qianhong, was Approved for Clinical Trials

Recently, Changzhou Qianhong Bio-Pharma targeted anti-cancer Class 1 new drug QHRD110 capsules was approved for clinical trials.

[Medicilon Assist] QHRD110 Capsules, a Class 1 Anti-cancer Drug Targeted by Qianhong, was Approved for Clinical Trials

Medicilon Helps Hangzhou Dac Biotechnology Muc1-ADC Get Clinical Approval

Recently, a recombinant humanized anti-MUC1 monoclonal antibody-Tub201 coupling agent (hereinafter referred to as "Muc1") for the treatment of advanced solid tumor class 1 ADC drug injection from Dac Biotechnology was approved for clinical use. This is the first clinically approved Muc1-ADC drug in China.

Medicilon Helps Hangzhou Dac Biotechnology Muc1-ADC Get Clinical Approval

[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials

Recently, the orphan drug KBMAB-16 (intravenous injection of tumor necrosis factor-α inhibitor), a major project of a well-known Chinese pharmaceutical company located in Chengdu, was successfully approved for clinical trial application (IND) by the US Food and Drug Administration (US FDA).

[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials

Medicilon's "New Drugs + AI Innov Forum" was successful held

When AI accurately predicts the "difficult” protein 3D structure; When AI completes the new drug design within 21 days; When AI discovers a new mechanism

Medicilon's "New Drugs + AI Innov Forum" was successful held

Global

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880(U.S. - West Coast)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy

-->